OBJECTIVE： To compare the efficacy and safety of Sodium hyaluronate versus Carbomer， Polyethylene glycol， Tobramycin and Dexamethasone in the treatment of glaucoma with cataract. METHODS： 464 glaucoma patients with cataract were randomly divided into group A （116 cases）， group B （116 cases）， group C （116 cases） and group D （116 cases）. All patients received intraocular lens implantation；1-1.5 cm to Tramycin and Dexamethasone eye ointment，3-5 times a day. Based on it， group A received 1-2 Sodium hyaluronate eye drops， 4 times a day. Group B received 1 Carbomer eye drop， 3-5 times a day. Group C received 1-2 Polyethylene glycol eye drops， 3-5 times a day. Group D received Tobramycin and dexamethasone eye ointment， 1-1.5 cm every times， 1-3 times a day. They treated for 1 month. Clinical efficacy， recovery of visual acuity and ocular surface functions [dry eye symptom score， tear film break-up time （BUT）， corneal fluorescein staining （CFS）， basal tear secretion （SIt）， ocular surface disease index （OSDI）] and the incidence of adverse reactions in all groups were observed. RESULTS： The total effective rate sorted，patients with visual acuity higher than 0.6，BUT，OSDI by group A＞group B＞group C＞group D， with significant differences （P＜0.05）. patients with visual acuity in 0.3-0.6， 0.1-0.3 and lower than 0.1，drycye symptom score，CFS，SIt in group A was less than group B， which was less than group C and group D， with significant differences （P＜0.05）. The incidence of adverse reactions in group A was lower than group B， C， D， with significant differences （P＜0.05）， but there was no significant difference in group B， C， D （P＞0.05）. CONCLUSIONS： Sodium hyaluronate shows superior efficacy and safety to Carbomer， Polyethylene glycol， Tobramycin and Dexamethasone in the treatment of glaucoma with cataract， it can significantly improve visual acuity and ocular surface function.